Fibroblast-Mimicking nanodecoys for Multi-Target antiangiogenesis in the inflammation treatment

• Published in: Materials & design 2022-10, Vol.222, p.111096, Article 111096
• Main Authors: Sun, Lizhong, Luo, Jun, Han, Mingyue, Li, Jianshu, Tao, Siying, Yang, Jiaojiao, Li, Jiyao
• Format: Article
• Language: English
• Subjects: Antiangiogenesis; Fibroblast membrane-camouflaged nanoparticle; LPS-induced inflammation; Neovascularization; Pro-angiogenic factor
• ISSN: 0264-1275; 1873-4197
• DOI: 10.1016/j.matdes.2022.111096

[Display omitted] •Fibroblast membrane-camouflaged nanoparticles with high surface expression of toll-like receptor 4 were fabricated for antiangiogenesis in the inflammation treatment.•Fibroblast membrane-camouflaged nanoparticles were an effective and safe cell membrane-based nanotherapeutics in the antiangiogenic therapy in vitro and in vivo.•The feasible mechanism for antiangiogenesis of fibroblast membrane-camouflaged nanoparticles was clearly and comprehensively described, which was attributed to inhibition of various pro-angiogenic factors via NF-κB signaling pathway.•The anti-angiogenic effects of fibroblast membrane-camouflaged nanoparticles were confirmed with the help of high throughput sequencing, bioinformatics analysis, and molecular biology techniques, etc. Localized inhibition of angiogenesis is an attractive therapeutic strategy for exogenous mediators-induced inflammation. Here, inspired by the unique biointerface of the natural cell membrane, we develop an endogenous cell membrane-derived biomimetic nanosystem (fibroblast membrane-camouflaged nanoparticles, FB@NPs) for blocking angiogenesis in the lipopolysaccharides (LPS)-induced inflammatory process. The fibroblast membrane coating provides as-fabricated nanoparticles with potent and specific binding ability to LPS, diverting these pathological toxins away and protecting resident fibroblasts. By efficient LPS neutralization and elimination, FB@NPs inhibit the production of a number of cross-regulated pro-angiogenic factors, and thereby greatly block inflammatory neovascularization. Besides, due to the self-recognition capability and inherent remarkable biocompatibility of these endogenous biomimetic nanoparticles, FB@NPs show highly desirable biosafety during the antiangiogenesis process in inflammation treatment. In summary, the novel exploration provides a promising route for developing next-generation biomimetic antiangiogenic nanoplatform.